These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Tolterodine for the treatment of overactive bladder.
    Author: Salvatore S, Serati M, Bolis P.
    Journal: Expert Opin Pharmacother; 2008 May; 9(7):1249-55. PubMed ID: 18422481.
    Abstract:
    BACKGROUND: The overactive bladder syndrome is a common condition affecting approximately 12% of men and women. It is extremely disturbing with a great impact on quality of life. Its treatment involves a combination of behavioural and pharmacological therapy. The latter includes antimuscarinic drugs such as tolterodine. OBJECTIVE: To review the safety and efficacy of tolterodine in the treatment of overactive bladder in comparison with other available antimuscarinic agents. METHODS: A Pubmed search was carried out differentiating randomised, clinical trials; longitudinal, retrospective studies; and metanalysis on the use of tolterodine for overactive bladder treatment. In the comparison with other antimuscarinic agents, only randomised, clinical trials were considered. RESULTS/CONCLUSION: Tolterodine is available as immediate- or extended-release formulations. It has been extensively evaluated with long-term, randomised trials for safety and efficacy showing a significant improvement in overactive bladder symptoms with an excellent tolerability profile.
    [Abstract] [Full Text] [Related] [New Search]